A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis (MOTION - JAPAN)

This study is currently recruiting participants.
Verified November 2013 by Biogen Idec
Biogen Idec Research Ltd.
Information provided by (Responsible Party):
Biogen Idec
ClinicalTrials.gov Identifier:
First received: August 2, 2013
Last updated: November 1, 2013
Last verified: November 2013

This is a multicenter study conducted in 2 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B is an open-label extension period. The primary objective of the double-blind study (Part A) is to assess the effect of Prolonged-Release Fampridine, treatment on walking speed, in Japanese patients with Multiple Sclerosis. The secondary objectives of the double-blind portion of the study are to evaluate the safety and tolerability of prolonged-release Fampridine in this study population. The primary endpoint of the open-label extension study (Part B) is to evaluate the long-term safety profile of prolonged-release Fampridine.

Condition Intervention Phase
Multiple Sclerosis, Remittent Progressive
Multiple Sclerosis, Primary Progressive
Relapsing-Remitting Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Drug: Placebo
Drug: fampridine (BIIB041)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension

Resource links provided by NLM:

Further study details as provided by Biogen Idec:

Primary Outcome Measures:
  • The proportion of subjects who show a consistent improvement in walking speed [ Time Frame: Part A (Up to 21 Weeks) ] [ Designated as safety issue: No ]
  • Numer of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Part B (54 Weeks) ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Part A (Up to 21 Weeks) ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 128
Study Start Date: August 2013
Estimated Study Completion Date: April 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Part A Placebo
Part A Placebo orally twice daily
Drug: Placebo
Placebo orally twice daily
Experimental: Part A fampridine (BIIB041)
Part A fampridine (BIIB041) 10mg orally twice daily
Drug: fampridine (BIIB041)
fampridine (BIIB041) 10mg orally twice daily
Experimental: Part B fampridine (BIIB041)
Part B fampridine (BIIB041) 10mg orally twice daily
Drug: fampridine (BIIB041)
fampridine (BIIB041) 10mg orally twice daily


Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Part A

To be eligible to participate in Part A, candidates must meet the following eligibility criteria at screening or at the timepoint specified in the individual eligibility criterion listed (potential subjects who fail screening may be rescreened 1 time):

  1. Must have a diagnosis of primary-progressive, secondary progressive, progressive relapsing, or relapsing-remitting MS as defined by the revised McDonald Committee criteria ([Lublin and Reingold 1996; McDonald 2001; Polman 2005]) of at least 2 months duration.
  2. Must be able to complete the T25FW with or without a walking aid in an average of 8 to 45 seconds at the screening visit.

Part B

To be eligible to participate in Part B, candidates must meet the following criteria at the Week 21 visit in Part A, which is the first visit for Part B:

1. Completed all visits in Part A of the study.

Exclusion Criteria:

  1. Known allergy to pyridine-containing substances, or any of the inactive ingredients of the prolonged-release fampridine tablet
  2. Any prior history of seizures, epilepsy, or other convulsive disorder, with the exception of febrile seizures in childhood, or prior history of epileptiform activity on electroencephalogram.
  3. Any form of renal impairment as defined by a creatinine clearance (CrCl) of <80 mL/min (estimated by the central laboratory).
  4. Known history of cardiac arrhythmia or cardiac conduction disorders requiring medical or surgical intervention, or any clinically significant ECG abnormality (as determined by the Investigator) at the screening visit or Day 1.
  5. Any prior treatment with fampridine (4 AP) or 3,4 diaminopyridine in any formulation.
  6. Treatment with an investigational drug or approved therapy for investigational use within 30 days (or 5 half lives, whichever is longer) prior to the screening visit.
  7. Participation in an investigational study (with the exception of observational studies) within 30 days prior to the screening visit or plans to enroll in another interventional investigational study at any time during this study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01917019

Contact: Biogen Idec neurologyclinicaltrials@biogenidec.com

Research Site Recruiting
Chiba, Japan
Research Site Recruiting
Fuchu, Japan
Research Site Recruiting
Morioka, Japan
Research Site Recruiting
Niigata, Japan
Research Site Recruiting
Osaka, Japan
Research Site Recruiting
Sapporo, Japan
Research Site Recruiting
Sapporo-Shi, Japan
Research Site Recruiting
Tokyo, Japan
Research Site Recruiting
Yamaguchi, Japan
Sponsors and Collaborators
Biogen Idec
Biogen Idec Research Ltd.
  More Information

No publications provided

Responsible Party: Biogen Idec
ClinicalTrials.gov Identifier: NCT01917019     History of Changes
Other Study ID Numbers: 218MS304
Study First Received: August 2, 2013
Last Updated: November 1, 2013
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency (PMDA)

Keywords provided by Biogen Idec:

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Multiple Sclerosis, Relapsing-Remitting
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes
Potassium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 21, 2014